

October 24-26, 2019

Zuckerman Research Center
New York, NY

Advances in the Management of Bladder and Kidney Cancer

A MULTIDISCIPLINARY APPROACH



mskcc.org/urologycourse



Memorial Sloan Kettering
Cancer Center



The aim of this program, presented by faculty from Memorial Sloan Kettering (MSK) and invited speakers, is to highlight new developments in the multidisciplinary management of bladder and kidney cancer. This will include insights into the ongoing cancer research in the field and at MSK.

The course objective is to advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer.

The program will include comprehensive state-of-the art lectures and discussions encouraging the exchange of ideas between faculty (radiologists, pathologists, surgeons, radiation oncologists, and medical oncologists) and the audience. Discussions will center on the multidisciplinary management of bladder and kidney cancer.

Educational Objectives

- To present a multidisciplinary approach to the management of bladder and kidney cancer including surgery, medical oncology, and radiation therapy.
- To advance and disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer

Target Audience

The intended audience includes urologists, urologic-oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, and allied health professions.

For course details and registration, visit:
mskcc.org/urologycourse

MSK Course Directors



James A. Eastham, MD, FACS
Chief, Urology Service
Peter T. Scardino Chair in Oncology



Jonathan E. Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W. Ercklentz Chair

MSK Program Planning Committee



Bernard H. Bochner, MD, FACS
Attending Surgeon
Urology Service
Sir Murray Brennan Chair in Surgery



Abraham A. Hakimi, MD
Assistant Attending Surgeon
Urology Service



Gopakumar V. Iyer, MD
Assistant Attending
Bladder Cancer Section Head
Genitourinary Oncology Service



Martin H. Voss, MD
Assistant Attending
Genitourinary Oncology Service



Memorial Sloan Kettering
Cancer Center

COURSE FACULTY

Invited Course Faculty

**Arjun Balar, MD**

Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
NYU Perlmutter Cancer Center

**James M. McKiernan, MD**

Chairman, Urologist-in-Chief
Department of Urology
Columbia University/NewYork-Presbyterian

**Brian Shuch, MD**

Associate Professor of Urology
Kidney Cancer Program Director
Department of Urology
UCLA School of Medicine

**R. Houston Thompson, MD**

Professor of Urology
Department of Urology
Mayo Clinic

Keynote Speaker

**Brian I. Rini, MD, FACP**

Professor of Medicine
Lerner College of Medicine Leader, GU Program
Director, Experimental Therapeutics Fellowship Program
Hematology and Oncology & Glickman Urological and Kidney Institute
Cleveland Clinic Taussig Cancer Institute

MSK Course Faculty

Oguz Akin, MD

Attending Radiologist
Director of Body MRI
Department of Radiology

Hikmat Al-Ahmadie, MD

Associate Attending Pathologist
Genitourinary Pathology

Charlotte E. Ariyan, MD, PhD

Associate Attending Surgeon
Gastric and Mixed Tumor Service

Dean F. Bajorin, MD

Attending Physician
Frederick R. Adler Senior Faculty Chair
Genitourinary Oncology Service
Professor of Medicine, Weill Cornell Medical College

Bernard H. Bochner, MD, FACS

Attending Surgeon
Urology Service
Sir Murray Brennan Chair in Surgery

Eugene K. Cha, MD

Assistant Attending Surgeon
Urology Service

Timothy A. Chan, MD, PhD

Vice Chair and Attending Physician
Department of Radiation Oncology
Director, Division of Translational Oncology
Directory, Immunogenomics and
Precision Oncology Platform
Member, Human Oncology and
Pathogenesis Program

Marie Carlo, MD

Assistant Attending
Genitourinary Oncology Service

Jonathan A. Coleman, MD

Associate Attending Surgeon
Urology Service

Timothy F. Donahue, MD

Associate Attending Surgeon
Urology Service

S. Machele Donat, MD, FACS

Attending Surgeon
Urology Service

Jeremy C. Durack, MD, MS

Attending Radiologist
Interventional Radiology Service

James A. Eastham, MD, FACS

Chief, Urology Service
Peter T. Scardino Chair in Oncology

Darren R. Feldman, MD

Associate Attending
Genitourinary Oncology Service

Samuel A. Funt, MD

Assistant Attending
Genitourinary Oncology Service

Alvin C. Goh, MD

Associate Attending Surgeon
Urology Service

Abraham A. Hakimi, MD

Assistant Attending Surgeon
Urology Service

Harry W. Herr, MD

Attending Surgeon
Urology Service

Gopakumar V. Iyer, MD

Assistant Attending
Bladder Cancer Section Head
Genitourinary Oncology Service

Marisa A. Kollmeier, MD

Associate Attending Physician
Chair, Radiation Oncology Quality Assurance
Brachytherapy Service

Chung-Han Lee, MD, PhD

Assistant Attending
Genitourinary Oncology Service

Robert J. Motzer, MD

Attending
Genitourinary Oncology Service

Eugene Pietzak, MD

Assistant Attending Surgeon
Urology Service
Brachytherapy Service

Victor E. Reuter, MD

Vice Chair, Department of Pathology
Director, Genitourinary Pathology
Director, Genitourinary Pathology Fellowship

Paul Russo, MD

Attending Surgeon
Urology Service
Professor of Urology, Weill Cornell College of Medicine

Jonathan E. Rosenberg, MD

Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W. Ercklentz Chair

Min Yuen Teo, MD

Assistant Attending
Genitourinary Oncology Service

Martin H. Voss, MD

Assistant Attending
Genitourinary Oncology Service

 Join the conversation:

#MSKurologyCME

@MSKCME

SCHEDULE



Thursday, October 24

Lunch and Registration	12:00 PM
Bladder MODERATOR: Timothy F. Donahue, MD Updated on Natural History of High Risk NIMBC Bernard H. Bochner, MD, FACS NMIBC Molecular Biology Eugene Pietzak, MD New Detection Technologies: Blue Light and NBI James M. McKiernan, MD	1:00 PM 1:15 PM 1:40 PM
Bladder MODERATOR: Bernard H. Bochner, MD, FACS Management of BCG - Unresponsive NMIBC Eugene K. Cha, MD Role of Checkpoint Inhibitors for NMIBC Dean F. Bajorin, MD Case Discussions - NIMBC BCG Shortage; Optimal BCG, Selection for Early Cystectomy; Persistent Positive Cytology (Natural History, Surveillance vs. Therapy) Harry W. Herr, MD Dean F. Bajorin, MD Eugene K. Cha, MD James M. McKiernan, MD	2:00 PM 2:15 PM 2:30 PM
Break	3:00 PM
Kidney (Localized) MODERATOR: Jonathan A. Coleman, MD SRM – Epidemiology and Treatment Molecular (overtreatment) Abraham A. Hakimi, MD Biopsy Victor E. Reuter, MD Ablation Jeremy C. Durack, MD, MS Surveillance and Genomics Brian Shuch, MD	3:10 PM 3:25 PM 3:40 PM 3:55 PM
Kidney MODERATOR: Abraham A. Hakimi, MD Novel Imaging in RCC Oguz Akin, MD Case Discussions Multifocal Renal Masses, SRM in Elderly Abraham A. Hakimi, MD Jonathan A. Coleman, MD Paul Russo, MD Brian Shuch, MD Jeremy C. Durack, MD, MS	4:10 PM 4:30 PM
Adjourn	5:00 PM

Friday, October 25

Breakfast	7:30 AM
Keynote Address Department of Medicine Grand Rounds MODERATOR: Jonathan E. Rosenberg, MD Emerging Paradigms in the Upfront Management of Metastatic Kidney Cancer Brian I. Rini, MD, FACP Q&A	8:00 AM 8:45 AM
Break	9:00 AM
Kidney (Locally Advanced) MODERATOR: Abraham A. Hakimi, MD Partial vs Radical for >= pT1b Paul Russo, MD LN Dissection R. Houston Thompson, MD Perioperative Therapy in the Non-metastatic Setting Martin H. Voss, MD Q&A	9:15 AM 9:30 AM 9:45 AM 10:05 AM
Kidney MODERATOR: Abraham A. Hakimi, MD Case Discussions Large Renal Masses, Node Positive, Solitary Kidney	10:15 AM
Break	11:00 AM
Bladder MODERATOR: Gopakumar V. Iyer, MD Neoadjuvant Therapy for Cis-eligible Patients (Cisplatin-based Chemotherapy, IO+Chemotherapy Trials) Gopakumar V. Iyer, MD Adjuvant Therapy for MIBC (including data on standard and novel therapies) Min Yuen Teo, MD Importance of Germline Mutations in Urothelial Cancer Marie Carlo, MD	11:10 AM 11:25 AM 11:35 AM
Bladder MODERATOR: Timothy F. Donahue, MD Open vs Robotic Surgery for MIBC: Update of Current data Bernard H. Bochner, MD, FACS RARC: How to. Tips and Tricks Alvin C. Goh, MD Case Discussions Bernard H. Bochner, MD, FACS Eugene K. Cha, MD Alvin C. Goh, MD Jonathan A. Coleman, MD James M. McKiernan, MD	11:45 AM 12:00 PM 12:20 PM

SCHEDULE



Lunch	12:30 PM
Kidney (Metastatic) MODERATOR: Martin H. Voss, MD 2nd Line Therapy and Beyond: Approved Agents and Their Application in the Post-IO Space Chung-Han Lee, MD, PhD Risk Stratification and Molecular Classifiers in the Metastatic Setting Martin H. Voss, MD Case Discussions Chung-Han Lee, MD, PhD Robert J. Motzer, MD Marie Carlo, MD	1:30 PM 1:50 PM 2:20 PM
Break	2:50 PM
Bladder MODERATOR: Dean F. Bajorin, MD Molecular Biology of MIBC - Role in Bladder Preservation Gopakumar V. Iyer, MD Trimodal Therapy for MIBC Marisa A. Kollmeier, MD Case Discussions Bladder Preservation Gopakumar V. Iyer, MD Marisa A. Kollmeier, MD Harry W. Herr, MD James M. McKiernan, MD	3:00 PM 3:20 PM 3:35 PM
Bladder MODERATOR: Gopakumar V. Iyer, MD Upper Tract TCC Molecular Differences and Clinical Management of UTCC Jonathan A. Coleman, MD Histologic Variants of Bladder Cancer Hikmat Al-Ahmadie, MD Case Discussions Clinical Management of Histologic Variants Bernard H. Bochner, MD, FACS Jonathan E. Rosenberg, MD S. Machele Donat, MD, FACS Marisa A. Kollmeier, MD Hikmat Al-Ahmadie, MD	4:00 PM 4:15 PM 4:30 PM
Adjourn	5:00 PM

Saturday, October 26

Breakfast	7:30 AM
Kidney/ Bladder/ Immunotherapy MODERATOR: Gopakumar V. Iyer, MD Biologic Principles Behind Immune-oncology Timothy A. Chan, MD, PhD Surgical Safety in IO Treated Patients Charlotte E. Ariyan, MD, PhD IO Tox Management Samuel A. Funt, MD	8:00 AM 8:20 AM 8:40 AM
Kidney (Metastatic, Multidisciplinary) MODERATOR: Paul Russo, MD Cytoreduction + Metastasectomy Paul Russo, MD Case Discussions Paul Russo, MD Marie Carlo, MD Darren R. Feldman, MD	9:00 AM
Kidney (Metastatic) MODERATOR: Abraham A. Hakimi, MD Familial Predisposition Syndromes and Germline Testing in RCC Marie Carlo, MD Systemic Therapy for Metastatic ncRCC Darren R. Feldman, MD Emerging Regimens for Metastatic RCC Chung-Han Lee, MD, PhD	9:40 AM 10:00 AM 10:20 AM
Bladder MODERATOR: Dean F. Bajorin, MD IO Therapy for Advanced Bladder Cancer: Data for IO in the 1st Line Metastatic Setting Jonathan E. Rosenberg, MD Predictive Biomarkers and Novel Metastatic Options (ADC, FGFR3 Inhibition) Arjun Balar, MD Case Discussions Jonathan E. Rosenberg, MD Samuel A. Funt, MD Arjun Balar, MD	10:30 AM 10:50 AM 11:10 AM
Symposium Adjourn	11:30 AM

REGISTRATION

Registration Fees	Early*	General
Physicians (MDs, PhDs & DOs)	\$500	\$600
Advanced Practice Providers	\$350	\$450
Residents, Fellows, Nurses & Other Healthcare Providers	\$200	\$300
Industry Professionals**	\$900	\$1,100

Register online:

mskcc.org/urologycourse

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- **MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners.** If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- **MSK employee registration is complimentary.** However, you must complete course registration in order to attend this course.

***Early registration rates expire August 23, 2019.**

****Industry professionals** may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Course Location

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY

Accommodations

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, visit: mskcc.org/cme

Contact

Memorial Sloan Kettering Cancer Center
Office of Continuing Medical Education
w: mskcc.org/cme
e: cme@mskcc.org



Memorial Sloan Kettering
Cancer Center



ZUCKERMAN
RESEARCH CENTER

ACCREDITATION



Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **16.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **16.00 Medical Knowledge MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.